Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN033 in advanced malignant tumors
NCT06770881Phase 2Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of JSKN033 in advanced malignant solid tumor, sponsored by Alphamab Oncology. Primary endpoints: Dose-limiting toxicity up to 12 months, Maximum Tolerated Dose or Recommended Phase II Dose up to 12 months and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
JSKN033
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT06770881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770881.